Since no alternative test is available to replace it, we have initiated a trial with the purpose of establishing whether Galectin-3 (Gal-3) serum level and/or the patients immune response to PSA and Gal-3 antigens could complement the PSA test as diagnostic tools for prostate cancer patients. Here, LGALS3 is linked to Familial prostate cancer.